Glaukos
Logotype for Glaukos Corporation

Glaukos (GKOS) investor relations material

Glaukos Q4 2025 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Glaukos Corporation
Q4 2025 earnings summary17 Feb, 2026

Executive summary

  • Achieved record Q4 2025 consolidated net sales of $143.1M, up 36% year-over-year, and full-year 2025 net sales of $507.4M, up 32% from 2024.

  • U.S. Glaucoma Q4 net sales grew 53% year-over-year to $86.4M; global Glaucoma Q4 net sales rose 42% year-over-year to $119.2M.

  • Celebrated surpassing $500M in annual sales, 10th IPO anniversary, and broke ground on a new facility in Alabama.

  • Advanced pipeline with launches of iDose TR and Epioxa, supporting future growth.

  • Positioned for continued growth in 2026, driven by iDose TR and Epioxa launches.

Financial highlights

  • Q4 U.S. glaucoma net sales reached $86.4M, up 53% year-over-year, with iDose TR contributing ~$45M.

  • International glaucoma net sales were $32.8M, up 18% year-over-year (13% constant currency).

  • Corneal health franchise net sales were $24M, up 12% year-over-year, with Photrexa at $21.4M.

  • Q4 2025 gross margin was (1%) GAAP due to a $112.9M non-cash impairment; non-GAAP gross margin was 85% vs. 82% in Q4 2024.

  • Q4 2025 GAAP net loss was $133.7M ($2.32/share); non-GAAP net loss was $16.4M ($0.28/share).

Outlook and guidance

  • Reaffirmed 2026 net sales guidance of $600M–$620M, implying over 20% growth at midpoint.

  • U.S. glaucoma expected to grow ~30% year-over-year in 2026, driven by iDose TR.

  • International glaucoma projected to grow high single digits, with some headwinds from competitive launches.

  • Corneal health expected to grow modestly, with volatility during Epioxa transition.

  • Sequential improvement anticipated each quarter in 2026 for iDose TR.

Impact of Photrexa to Epioxa transition?
Key drivers for 2026 net sales guidance?
Underlying Q4 operational profitability?
iDose TR re-administration strategy
Epioxa Q2/Q3 revenue volatility drivers
OpEx growth vs. operating leverage in 2026
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next Glaukos earnings date

Logotype for Glaukos Corporation
Q1 202629 Apr, 2026
Glaukos
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Glaukos earnings date

Logotype for Glaukos Corporation
Q1 202629 Apr, 2026

The essential earnings season companion

The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Glaukos Corporation develops and commercializes medical devices and pharmaceuticals for the treatment of glaucoma, corneal disorders, and retinal diseases. The company is known for its minimally invasive surgical technologies and ophthalmic drug delivery platforms. The company is headquartered in Aliso Viejo, California, and its shares are listed on the NYSE.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage